417 related articles for article (PubMed ID: 29322803)
1. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
[TBL] [Abstract][Full Text] [Related]
2. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
3. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
4. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
5. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
6. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions.
McGowan K; Ivanovski S; Acton C
Aust Dent J; 2018 Jun; 63(2):202-207. PubMed ID: 29432652
[TBL] [Abstract][Full Text] [Related]
8. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
9. The Prevention of Medication-related Osteonecrosis of the Jaw.
Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
[TBL] [Abstract][Full Text] [Related]
10. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report.
Penoni DC; Canellas JVS; Silami MANC; Sader F; Pimentel GS; Leão ATT
Arch Endocrinol Metab; 2023 May; 67(4):e000612. PubMed ID: 37252700
[TBL] [Abstract][Full Text] [Related]
12. A case of nasal septal abscess caused by medication related osteonecrosis in breast cancer patient.
Maeda M; Matsunobu T; Kurioka T; Kurita A; Shiotani A
Auris Nasus Larynx; 2016 Feb; 43(1):93-6. PubMed ID: 26775849
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
[TBL] [Abstract][Full Text] [Related]
15. Medication--related osteonecrosis of the jaws. The first reported cases in the Baltic States and a literature review.
Zaleckas L; Stacevičius M; Proškutė D; Povilaitytė J
Stomatologija; 2015; 17(3):89-96. PubMed ID: 26879401
[TBL] [Abstract][Full Text] [Related]
16. Physicians' awareness of medication-related osteonecrosis of the jaw in patients with osteoporosis.
Supanumpar N; Pisarnturakit PP; Charatcharoenwitthaya N; Subbalekha K
PLoS One; 2024; 19(1):e0297500. PubMed ID: 38277387
[TBL] [Abstract][Full Text] [Related]
17. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
[TBL] [Abstract][Full Text] [Related]
18. Cooperation between physicians and dentists for osteonecrosis of the jaw: a 2022 Japanese survey.
Taguchi A; Hagino H; Inoue D; Endo N; Society JO
J Bone Miner Metab; 2023 Nov; 41(6):829-837. PubMed ID: 37516668
[TBL] [Abstract][Full Text] [Related]
19. Patients Receiving Parenteral Bisphosphonates for Malignant Disease and Having Developed an Atypical Femoral Fracture Are at Risk of Concomitant Osteonecrosis of the Jaw: An Evidence-Based Review.
Graves LL; Bukata SV; Aghazadehsanai N; Chang TI; Garrett NR; Friedlander AH
J Oral Maxillofac Surg; 2016 Dec; 74(12):2403-2408. PubMed ID: 27376180
[TBL] [Abstract][Full Text] [Related]
20. Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2.
Coropciuc RG; Grisar K; Aerden T; Schol M; Schoenaers J; Politis C
Br J Oral Maxillofac Surg; 2017 Oct; 55(8):787-792. PubMed ID: 28760314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
